Recent Company News

• 05:28 PM ET Feb 17, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 06:23 AM ET Feb 17, 2026
  

  Autolus Therapeutics initiated buy at HC Wainwright ($1.40, 0.00)

• 06:30 AM ET Feb 13, 2026
  

  Autolus Therapeutics assumed buy at Jefferies ($1.38, 0.00)

• 02:00 PM ET Feb 02, 2026
  

  StreetAccount Summary - Private Company Weekly Recap - Week of 26-Jan

• 04:11 PM ET Jan 26, 2026
  

  Autolus Therapeutics discloses master service agreement with AGC Biologics S.p.A for manufacture and supply of lentiviral vector - 8-K ($1.39, 0.00)

• 07:09 AM ET Jan 12, 2026
  

  Autolus Therapeutics guides Q4 AUCATZYL revenue ~$24M ($1.81, 0.00)

• 09:04 AM ET Jan 06, 2026
  

  Autolus Therapeutics to evaluate automated manufacturing of AUCATZYL (obe-cel) on the Cellares Cell Shuttle platform ($1.86, 0.00)

• 09:33 PM ET Dec 10, 2025
  

  NICE recommends Autolus's Aucatzyl to treat relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in adults

• 04:08 PM ET Dec 08, 2025
  

  Autolus Therapeutics presents updated clinical data from the CARLYSLE Trial in patients with severe refractory systemic lupus erythematosus at the ASH Annual Meeting 2025 ($1.59, 0.00)

• 08:39 AM ET Dec 08, 2025
  

  Autolus Therapeutics reports initial clinical data in pediatric r/r B-ALL patients and other oncology data presented at ASH ($1.55, 0.00)